ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Predicting HbA1c Target Achievement in Type 2 Diabetes: A Retrospective Single-Centre Nomogram Derived From National MMC-Standardised Management.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assessed the effectiveness of standardized management implemented by the National Metabolic Management Center (MMC) for patients with type 2 diabetes. The goal was to develop a nomogram for predicting HbA1c target achievement. Methods: A retrospective single-centre study was conducted, including 853 type 2 diabetes patients enrolled in the National Standardized Metabolic Disease Management Center at the Third People's Hospital of Datong City from June 2019 to June 2020. After one year of MMC's standardized management, factors influencing HbA1c achievement were identified through univariate and multivariate analyses to establish a predictive model. Missing data were handled using appropriate imputation methods. Model accuracy and performance were assessed using internal validation and ROC curve analysis. Results: Significant improvements were observed following MMC's standardized management, including reductions in SBP, FBG, Hb, HCT, MPV, γ-GT, ALB, TG, TC, HbA1c, and LDL-c levels (P<0.05), and increases in AST, BUN, Cr, UA, and HDL-c levels (P<0.05). The absolute HbA1c level decreased, and the rate of achieving the HbA1c target (<7%) was significantly enhanced (P<0.05). Multivariate analysis identified FBG and HCT as independent protective factors for HbA1c achievement, while ALB was a risk factor. The developed predictive model exhibited favorable discriminative ability (c-index: 0.747, 95% CI: 0.703-0.790), confirmed by decision curve analysis. Conclusion: Standardized MMC management may guide care for type 2 diabetes patients. The predictive model established in this study may assist in improving HbA1c achievement rates, although external validation is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.